PMID- 34131807
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20230508
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 71
IP  - 2
DP  - 2022 Feb
TI  - Evaluation of efficacy and toxicity of nivolumab combined with or without 
      docetaxel in patients with advanced NSCLC.
PG  - 267-276
LID - 10.1007/s00262-021-02964-x [doi]
AB  - BACKGROUND: The combination of PD-1/PD-L1 inhibitor and chemotherapy has been 
      clinically confirmed to be beneficial as the first-line treatment of patients 
      with advanced NSCLC. This study aimed to assess the effect of 
      nivolumab + docetaxel versus nivolumab monotherapy in patients with NSCLC after 
      the failure of platinum doublet chemotherapy. MATERIALS AND METHODS: The efficacy 
      and toxicity of nivolumab + docetaxel combination therapy versus nivolumab 
      monotherapy were compared in this retrospective study. Primary endpoint of the 
      study was progression-free survival (PFS), and the secondary endpoints were 
      objective response rate (ORR), overall survival (OS), and toxicity. RESULTS: 
      Between November 2017 and December 2019, 77 patients were included in this study, 
      with 58 patients in the nivolumab group and 19 in the nivolumab + docetaxel 
      group. The median follow-up was 18 months, and the PFS was 8 months for patients 
      receiving nivolumab + docetaxel and 2 months for those receiving nivolumab alone 
      (p = 0.001), respectively. Nivolumab + docetaxel showed superior OS compared with 
      nivolumab, with the median OS unreached versus 7 months (p = 0.011). Among 
      patients without EGFR/ALK variation, compared to nivolumab monotherapy, 
      nivolumab + docetaxel showed better PFS (p = 0.04) and OS (p  = 0.05). There was 
      no significant difference in grade 3-4 adverse events (AEs) between the two 
      groups (p = 0.253). CONCLUSIONS: The combination of nivolumab and docetaxel 
      demonstrated a meaningful improvement in progression-free survival and overall 
      survival compared to nivolumab monotherapy, in patients with NSCLC after the 
      failure of platinum doublet chemotherapy, irrespective of EGFR/ALK variation 
      status.
CI  - (c) 2021. The Author(s).
FAU - Wang, Yang
AU  - Wang Y
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Nie, Jun
AU  - Nie J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Dai, Ling
AU  - Dai L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Hu, Weiheng
AU  - Hu W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Chen, Xiaoling
AU  - Chen X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Ma, Xiangjuan
AU  - Ma X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Tian, Guangming
AU  - Tian G
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Han, Jindi
AU  - Han J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Han, Sen
AU  - Han S
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Wu, Di
AU  - Wu D
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Long, Jieran
AU  - Long J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Zhang, Ziran
AU  - Zhang Z
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China.
FAU - Fang, Jian
AU  - Fang J
AUID- ORCID: 0000-0002-3004-9708
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer 
      Hospital & Institute, Haidian District, 52# Fucheng Road, Beijing, 100142, China. 
      jianfang@bjcancer.org.
LA  - eng
GR  - Y-BMS2019-010/Chinese Society of Clinical Oncology - Bristol-Myers Squibb Cancer 
      Immunology Research Fund/
PT  - Comparative Study
PT  - Journal Article
DEP - 20210615
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 15H5577CQD (Docetaxel)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Docetaxel/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/administration & dosage
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC8783906
OTO - NOTNLM
OT  - ALK
OT  - Combination therapy
OT  - Docetaxel
OT  - EGFR
OT  - Nivolumab
OT  - Non-small cell Lung cancer
COIS- None of the authors have actual or potential conflicts of interest, including any 
      financial, personal or other relation- ships with other people or organizations 
      that could inappropriately influence this article, to declare.
EDAT- 2021/06/17 06:00
MHDA- 2022/02/08 06:00
PMCR- 2021/06/15
CRDT- 2021/06/16 06:56
PHST- 2020/12/28 00:00 [received]
PHST- 2021/05/09 00:00 [accepted]
PHST- 2021/06/17 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2021/06/16 06:56 [entrez]
PHST- 2021/06/15 00:00 [pmc-release]
AID - 10.1007/s00262-021-02964-x [pii]
AID - 2964 [pii]
AID - 10.1007/s00262-021-02964-x [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2022 Feb;71(2):267-276. doi: 
      10.1007/s00262-021-02964-x. Epub 2021 Jun 15.